AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27299459
Drug: Xuefu Zhuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefu Zhuyu Capsule (XFZY-CS) at 2.5% concentration
Trial: 27299459
Drug: Xuefu Zhuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefu Zhuyu Capsule (XFZY-CS) at 5% concentration
Trial: 19557206
Drug: Montelukast as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast as add-on therapy
Trial: 17577134
Drug: Methylprednisolone 500
RxNorm normalized name: methylprednisolone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 500 mg preoperatively
Trial: 16354313
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (n=142; 4 cycles of cisplatin 75 mg/m2 I.V. on day 1 with etoposide 100 mg/m2 I.V. on days 1-3 followed by 4 cycles of topotecan 1.5 mg/m2 I.V. on days 1-5)
Trial: 16354313
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy (n=142; same doses of cisplatin/etoposide on cycles 1, 3, 5, and 7 and topotecan on cycles 2, 4, 6, and 8)
Trial: 10434322
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: Planned consultation and test injection before surgery
Trial: 2277574
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenylhydantoin (DPH) 2.5 mg kg‐1
Trial: 7026817
Drug: Preferred medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred medication
Trial: 11346831
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT) plus manual therapy of the cervical spine (group I)
Trial: 11346831
Drug: Low-energy shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy shockwave therapy (group II)
Trial: 7822903
Drug: Hydroxyethylrutosides (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylrutosides (1 g twice daily for 4 weeks)
Trial: 3126638
Drug: NTG oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG oral spray (0.8 mg) in hydrosoluble solution (NTG-h)
Trial: 3126638
Drug: NTG oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG oral spray (0.8 mg) in liposoluble solution (NTG-I)
Trial: 3126638
Drug: NTG oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG oral spray (both formulations)
Trial: 11467238
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg)
Trial: 14520129
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Imipramine, Buspirone, Placebo)
Trial: 7899651
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg) in Group C0.5
Trial: 7899651
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg) in Group A0.5
Trial: 7899651
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine in Group C0
Trial: 7899651
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg) in Groups C0.5 and A0.5
Trial: 7933485
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.5 mg)
Trial: 2693031
Drug: Triflusal (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (platelet antiaggregant drug)
Trial: 31421670
Drug: MOFA (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOFA (0.2 g/kg fish oil preoperatively, followed by 48 h continuous infusion of 0.2 g/kg/d n3FA)
Trial: 31421670
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard ERAS therapy)
Trial: 27893184
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and antipsychotics (specific drugs not detailed)
Trial: 27893184
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs with cardiovascular risk
Trial: 15694243
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs
Trial: 27893184
Drug: Risk drugs
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk drugs
Trial: 27090863
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (150 μg single injection)
Trial: 26003273
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (300 IU daily for first 7 days, then daily until three follicles reach ≥17 mm)
Trial: 23880960
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg/day
Trial: 23880960
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch 30 g/day
Trial: 23880960
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no aspirin or resistant starch)
Trial: 20659577
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with formoterol (FOR) 12 μg BID plus tiotropium (TIO) 18 μg QD
Trial: 20659577
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) alone 18 μg QD
Trial: 19812401
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg daily for 6 weeks
Trial: 12970329
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg daily
Trial: 17967584
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2 mg plus vitamin B12 1 mg daily
Trial: 2188379
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily
Trial: 15479217
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR (30-120 mg) once daily
Trial: 15479217
Drug: Gliclazide MR
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide MR in combination therapy
Trial: 11242646
Drug: High-dose group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group: MMC at 8 mg/m2 on the day of surgery, and in weeks 4, 10, 16, and 22 after surgery; 6 capsules of UFT (600 mg in tegafur) daily for 6 months.
Trial: 11242646
Drug: Low-dose group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose group: MMC at 8 mg/m2 on the day of surgery; 3 capsules of UFT (300 mg in tegafur) daily for 6 months.
Trial: 16808624
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group
Trial: 1977079
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group
Trial: 7996525
Drug: Programmable subcutaneous
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmable subcutaneous infusion pump with terbutaline, adjusted to control uterine contraction frequency to < or = 4 contractions per hour.
Trial: 7996525
Drug: Oral terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline, average of 6.5 mg every four to six hours.
Trial: 3396249
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (100 mg IM bi-weekly for six months)
Trial: 31356008
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens extract (ESR - Permixon) 320 mg capsules per day for two years
Trial: 24012053
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of amoxicillin/clavulanic acid 625 mg orally every 8 h for 4 days after 24 h of intravenous administration
Trial: 24012053
Drug: 1-day course
RxNorm normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2 g intravenously for 24 h followed by oral placebo
Trial: 15000513
Drug: Acamprosate (1.998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (1.998 mg/day)
Trial: 7908821
Drug: discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: discontinuation of both anaesthetics
Trial: 22696144
Drug: Group LM
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group LM (19 ml of 0.25% levobupivacaine and 1 ml of 15% magnesium sulphate)
Trial: 22696144
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (20 ml of 0.25% levobupivacaine)
Trial: 17937959
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg fesoterodine
Trial: 17937959
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg fesoterodine
Trial: 15731540
Drug: Mucosal protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosal protection (teprenone 150 mg/day)
Trial: 15731540
Drug: Histamine2-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Histamine2-receptor antagonist (ranitidine 300 mg/day)
Trial: 15731540
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (rabeprazole 10 mg/day)
Trial: 11755937
Drug: tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 2.5 mg/day (n=20)
Trial: 11755937
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (n=23)
Trial: 9652276
Drug: In-line intravenous
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-line intravenous filters
Trial: 9652276
Drug: No in-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No in-line intravenous filters
Trial: 7892022
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg (slow-release formulation)
Trial: 3053312
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid regimen
Trial: 26118386
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (4 g intravenously then 1 g/h for 6 h)
Trial: 22695134
Drug: Weekly UV-B
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly UV-B in a tanning bed (group A)
Trial: 22695134
Drug: 1520-IU/d vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1520-IU/d vitamin D supplement (group B)
Trial: 18946298
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg spinal bupivacaine with intravenous phenylephrine infusion (0.25 microg . kg(‐1) . min(‐1))
Trial: 18946298
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg spinal bupivacaine with intravenous placebo infusion
Trial: 8857917
Drug: Medium cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium cholesterol diet (350 mg)
Trial: 8857917
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol diet (650 mg)
Trial: 1638340
Drug: Trichlormethiazide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichlormethiazide (4 mg/day)
Trial: 1638340
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment with close follow-up)
Trial: 3859954
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg PGE2 gel placed retroamnially by means of a balloon catheter
Trial: 6594721
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg PGE2 applied endocervically
Trial: 6594721
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 applied endocervically
Trial: 3859954
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PGE2 placed intravaginally in form of a single vaginal tablet
Trial: 22278334
Drug: CG100649 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG100649 (2 mg)
Trial: 22278334
Drug: CG100649 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG100649 (8 mg)
Trial: 10075616
Drug: Inhaled beclomethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone, 200 microg twice daily
Trial: 10075616
Drug: Oral montelukast,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast, 10 mg once daily at bedtime
Trial: 7734138
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of tyramine to raise systemic blood pressure
Trial: 1755532
Drug: Patient Controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Controlled Analgesia (PCA) with morphine (2 mg bolus, lock-out 5 min in recovery/intensive care, 15 min in surgical ward)
Trial: 1755532
Drug: Epidural Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Bupivacaine + Morphine (EBM) with bupivacaine (0.25%) and morphine (60 micrograms/ml) infused via epidural catheter for approximately 72 hours
Trial: 1755532
Drug: Epidural Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Morphine (EM) with morphine (0.05 mg/kg in 10 ml saline) injected on request up to the 3rd postoperative day
Trial: 6120272
Drug: Sulphinpyrazone 400
RxNorm normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphinpyrazone 400 mg twice daily
Trial: 26595551
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine at the time of infliximab infusion
Trial: 26595551
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine midway between infliximab infusions
Trial: 23471234
Drug: Recombinant t-PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant t-PA (0, 40, 200, and 1000 ng/mL)
Trial: 23471234
Drug: Intra-arterial bradykinin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial bradykinin infusion
Trial: 23471234
Drug: Intra-arterial bradykinin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial bradykinin infusion with enalapril
Trial: 20973856
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR + nicotine lozenge
Trial: 28922651
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch + nicotine lozenge
Trial: 12869836
Drug: PRO 2000
RxNorm normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO 2000 Gel
Trial: 12869836
Drug: BufferGel and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BufferGel and PRO 2000 Gel
Trial: 11031076
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solutions (2 and 5% NaCl) and thirsting
Trial: 11031076
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water ad libitum
Trial: 9100162
Drug: Sulodexide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (600 lipoprotein-lipase releasing units, intramuscularly, daily for 28 days)
Trial: 8261692
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 5 mg od
Trial: 8261692
Drug: Felodipine PT
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine PT 2.5 mg bid
Trial: 30041437
Drug: High-Protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Protein diet with three whole eggs per day (1.4 g protein kg‐1 day‐1)
Trial: 30041437
Drug: Normal-Protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-Protein diet void of eggs (0.8 g protein kg‐1 day‐1)
Trial: 27936999
Drug: Single-pill irbesartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pill irbesartan/amlodipine combination-based therapy for 12 weeks
Trial: 25166215
Drug: Pterygopalatine fossa
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pterygopalatine fossa injection with 1% xylocaine and 1:100,000 adrenaline
Trial: 25166215
Drug: Control (contralateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (contralateral side without injection)
Trial: 19238327
Drug: Talactoferrin 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talactoferrin 4.5 g/day
Trial: 19238327
Drug: Talactoferrin 9
RxNorm normalized name: Talactoferrin alfa
DrugBank: Talactoferrin alfa (DB05426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talactoferrin 9 g/day
Trial: 18547273
Drug: Duodenal levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal levodopa/carbidopa infusion
Trial: 7913683
Drug: beta‐adrenoceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐adrenoceptor antagonists (beta AA)
Trial: 7913683
Drug: calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium channel blockers (CCB)
Trial: 24318863
Drug: Planned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatment preceded by pretreatment genetic analysis
Trial: 24318863
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX regimen in planned treatment group
Trial: 24318863
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen in planned treatment group
Trial: 24318863
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX regimen in conventional treatment group
Trial: 24318863
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen in conventional treatment group
Trial: 17408924
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral clindamycin (600 mg) administered preoperatively
Trial: 17408924
Drug: Clindamycin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin administered preoperatively with continued therapy for 5 days
Trial: 17408924
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral clindamycin (600 mg)
Trial: 17408924
Drug: Clindamycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (single dose or 5-day therapy)
Trial: 10205637
Drug: Folifer-Z tablets
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folifer-Z tablets
Trial: 10205637
Drug: Fefol-Z capsules
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fefol-Z capsules
Trial: 2472826
Drug: Chemotherapy (streptozotocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (streptozotocin plus 5-fluorouracil)
Trial: 28533200
Drug: Beliefs about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs about Medicines Questionnaire (quantitative assessment)
Trial: 26522042
Drug: Clinpro XT
RxNorm normalized name: Clinpro 5000
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinpro XT light-curable fluoride varnish applied to buccal surfaces adjacent to brackets
Trial: 20528216
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (100 μg per day)
Trial: 17536122
Drug: Moderate multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate multivitamin and mineral supplementation (vitamin C 150.0 mg/day, vitamin E 24.0 mg/day, beta-carotene 4.8 mg/day)